Literature DB >> 10807001

Mechanisms and applications of immune stimulatory CpG oligodeoxynucleotides.

A M Krieg1.   

Abstract

Immune stimulation has been widely recognized as an undesirable side effect of certain antisense oligodeoxynucleotides (ODN) which can interfere with their therapeutic application. It is now clear that these dose-dependent immune stimulatory effects primarily result from the presence of an unmethylated CpG dinucleotide in particular base contexts ('CpG motif). The sequence-specific immune activation is not just an experimental artifact, but is actually a highly evolved immune defense mechanism whose actual 'goal' is the detection of microbial nucleic acids. In contrast to vertebrate DNA, in which CpG dinucleotides are 'suppressed' and are highly methylated, microbial genomes do not generally feature CpG suppression or methylation [1]. Immune effector cells such as B cells, macrophages, dendritic cells, and natural killer cells appear to have evolved pattern recognition receptors (PRR) that by binding the microbe-restricted structure of CpG motifs, trigger protective immune responses. Although the specific immune activation appears to have a variety of potential therapeutic applications, it is generally undesirable in antisense ODN. Immune stimulation may be avoided in antisense oligos by the selection of CpG-free target sequences, by the use of ODN backbones that do not support immune stimulation, or by selective modifications of the cytosine in any CpG dinucleotides.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10807001     DOI: 10.1016/s0167-4781(99)00147-5

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  23 in total

Review 1.  Modulation of antitumor responses by dendritic cells.

Authors:  Johannes Vieweg; Andrew Jackson
Journal:  Springer Semin Immunopathol       Date:  2005-01

Review 2.  Role of Toll-like receptors in infection and immunity: clinical implications.

Authors:  Patricia Cristofaro; Steven M Opal
Journal:  Drugs       Date:  2006       Impact factor: 9.546

3.  Safety evaluation of intravenously administered mono-thioated aptamer against E-selectin in mice.

Authors:  Shin-Ae Kang; Bilegtsaikhan Tsolmon; Aman P Mann; Wei Zheng; Lichao Zhao; Yan Daniel Zhao; David E Volk; Ganesh L-R Lokesh; Lynsie Morris; Vineet Gupta; Wajeeha Razaq; Hallgeir Rui; K Stephen Suh; David G Gorenstein; Takemi Tanaka
Journal:  Toxicol Appl Pharmacol       Date:  2015-06-03       Impact factor: 4.219

4.  Immunization against leishmaniasis by PLGA nanospheres encapsulated with autoclaved Leishmania major (ALM) and CpG-ODN.

Authors:  Mohsen Tafaghodi; Ali Khamesipour; Mahmoud R Jaafari
Journal:  Parasitol Res       Date:  2010-12-02       Impact factor: 2.289

5.  Preexposure of murine macrophages to CpG oligonucleotide results in a biphasic tumor necrosis factor alpha response to subsequent lipopolysaccharide challenge.

Authors:  T D Crabtree; L Jin; D P Raymond; S J Pelletier; C W Houlgrave; T G Gleason; T L Pruett; R G Sawyer
Journal:  Infect Immun       Date:  2001-04       Impact factor: 3.441

6.  Herpes simplex virus type 1 DNA is immunostimulatory in vitro and in vivo.

Authors:  Patric Lundberg; Paula Welander; Xiao Han; Edouard Cantin
Journal:  J Virol       Date:  2003-10       Impact factor: 5.103

7.  Comparison of multiple adjuvants on the stability and immunogenicity of a clade C HIV-1 gp140 trimer.

Authors:  Joseph P Nkolola; Ann Cheung; James R Perry; Darrick Carter; Steve Reed; Hanneke Schuitemaker; Maria Grazia Pau; Michael S Seaman; Bing Chen; Dan H Barouch
Journal:  Vaccine       Date:  2014-02-18       Impact factor: 3.641

8.  Protection of chickens against Escherichia coli infections by DNA containing CpG motifs.

Authors:  Susantha Gomis; Lorne Babiuk; Dale L Godson; Brenda Allan; Tannis Thrush; Hugh Townsend; Philip Willson; Edwin Waters; Rolf Hecker; Andrew Potter
Journal:  Infect Immun       Date:  2003-02       Impact factor: 3.441

9.  2'-O-methyl-modified phosphorothioate antisense oligonucleotides have reduced non-specific effects in vitro.

Authors:  Byong Hoon Yoo; Elena Bochkareva; Alexey Bochkarev; Tung-Chung Mou; Donald M Gray
Journal:  Nucleic Acids Res       Date:  2004-04-02       Impact factor: 16.971

10.  Advances in antisense oligonucleotide development for target identification, validation, and as novel therapeutics.

Authors:  Moizza Mansoor; Alirio J Melendez
Journal:  Gene Regul Syst Bio       Date:  2008-09-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.